-
EU looks to increase Etias travel authorisation fee from €7 to €20
Second-home owners and other visitors from the UK and US will need this from autumn 2026
-
What dangerous snakes are in France and what to do if you spot one
Anyone killing a snake risks a fine and potentially a prison sentence
-
Ryanair says flights over France must be protected from air traffic controller strikes
Strikes at start of the month cost airlines over €100 million as budget airline claims workers ‘wanted time off’
First Covid vaccine approved for EU today
Today's announcement by the European Medicines Agency paves the way for France's vaccination programme to start on time

The Covid-19 vaccine developed by Pfizer and BioNTech has today been authorised by the European Medicines Agency (EMA), one of the last formalities before vaccinations may begin.
It must now be approved by the European Commission, but its president, Ursula von der Leyen, has said this could happen today.
It’s a decisive moment in our efforts to deliver safe & effective vaccines to Europeans!
— Ursula von der Leyen (@vonderleyen) December 21, 2020
The @EMA_News just issued a positive scientific opinion on the #BioNTech / @pfizer vaccine.
Now we will act fast. I expect a @EU_Commission decision by this evening.
Ms von der Leyen said vaccination would now be able to start across the EU from December 27.
This follows approval of the vaccine for use in the UK – which involved an accelerated procedure for temporary permission (allowed by EU law) – and the USA.
The EMA said it was approving the vaccine on certain conditions, notably it should be given only to people aged over 16 and that the American and German firms that developed the vaccine should supply follow-up data on the vaccine for one year.
“This is really a historic scientific achievement," said EMA head Emer Cooke. “It is a significant step forward in our fight against the pandemic.”
The vaccine will be the first to be rolled-out in France and it is hoped that next year another, by Moderna, will receive approval in early January.
It will be offered first to residents in nursing homes and then rolled out progressively to groups deemed less at risk.
Other vaccines are also in the pipeline, from Oxford/AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica and CureVac.